Daxxify (daxibotulinumtoxinA-lanm)

Daxxify (daxibotulinumtoxinA-lanm) is covered only for the FDA-approved indication of cervical dystonia in adults (≥18 years); other indications are not covered. Approval (12 months) requires documentation of age and diagnosis, dosing of 125–250 units intramuscularly divided among affected muscles, and administration no more frequently than every 3 months.

"Daxxify is indicated for the treatment of cervical dystonia in adult patients."

Sign up to see full coverage criteria, indications, and limitations.